GemVax & KAEL Co.,Ltd. Logo

GemVax & KAEL Co.,Ltd.

Makes contamination controls for semiconductors & develops Alzheimer's therapeutics.

082270 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노11로 58, 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

GemVax & KAEL Co., Ltd. is a company with a dual-business structure. Its Environmental Control division manufactures and sells contaminant control solutions, including coating resins and filters, for the semiconductor and display industries. This established business provides the financial foundation for its Bio division, a clinical-stage biopharmaceutical arm focused on developing novel therapeutics. The Bio division's lead candidate is GV1001, a telomerase-derived peptide being developed as a treatment for neurodegenerative diseases, including Alzheimer's disease and Progressive Supranuclear Palsy, and is advancing into late-stage clinical trials.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for GemVax & KAEL Co.,Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-17 00:00
Major Shareholding Notification
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 47.6 KB
2025-09-16 00:00
Share Issue/Capital Change
주요사항보고서(제3자의신주인수권부사채매수선택권행사)
Korean 19.5 KB
2025-09-12 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 163.1 KB
2025-09-12 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.11)
Korean 3.3 MB
2025-09-05 00:00
Major Shareholding Notification
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 50.6 KB
2025-09-02 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-08-29 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 30.2 KB
2025-08-29 00:00
Registration Form
[정정제출요구]증권신고서(지분증권) (2025.11)
Korean 2.9 MB

Automate Your Workflow. Get a real-time feed of all GemVax & KAEL Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for GemVax & KAEL Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden KAN
KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea 217730
Karo Pharma AB Logo
Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.
Sweden KARO
KBIO COMPANY Inc. Logo
Using a plant-based platform to rapidly develop biologics for public health.
South Korea 038530
Keeps Biopharma Inc. Logo
Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.
South Korea 256940
Kidswell Bio Corporation Logo
Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.
Japan 4584
Kinarus Therapeutics Holding AG Logo
A specialty pharma firm developing and selling medicines for rare and specialty diseases.
Switzerland KNRS
KISSEI PHARMACEUTICAL CO.,LTD. Logo
Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.
Japan 4547
Klaria Pharma Holding AB Logo
Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.
Sweden KLAR

Talk to a Data Expert

Have a question? We'll get back to you promptly.